A future without heart attacks could save millions of lives. Company Verve Therapeutics Wants to use gene modification techniques such as CRISPR Selectively manipulate parts of the human genome that are responsible for heart attacks.
Low density lipoprotein (LDL) which is commonly called Bad cholesterol It is known that one of the main causes of cardiovascular disease is atherosclerosis (ASCVD). However, research has shown that if we inactivate certain genes, we can reduce the risk of heart attack. Verve Therapeutics to modify its genetic material Liver The patient sends up the problematic gene Disable.
In addition to LDL, triglyceride-rich lipoprotein (TRL) or lipoprotein a are other factors that lead to Heart attacks be. Verve’s treatment method specifically targets the genes that produce these molecules. The company is currently carrying out genetic modifications of two enzymes PCSK9 And ANGPTL3 And is reviewing the performance of this treatment.
Gene modification is performed only on adults
Verve emphasizes that the gene modification method is only on adults Uses and will not manipulate the genome sequence of oocytes, sperm, or embryos to avoid common moral challenges. Adults can do this of their own choosing.
Since heart attacks with Cholesterol accumulation Occurs in blood vessels, Verve treatment seeks to prevent this accumulation by altering metabolic behavior at the gene level. The company plans to begin clinical trials of the treatment soon with adults who have had high cholesterol and a heart attack due to inherited diseases. However, it is expected that in the future people Younger They can also use this treatment to prevent heart problems.
Verve has previously applied this treatment monkeys Had tested and was able to lower the level of bad cholesterol in the blood 59 percent Reduce. However, there are probably still years left until the completion of human trials, and the cost of this treatment could be a figure between 50 to 200 thousand dollars Be.